Assessing the Safety of Dapivirine Gel and Film Formulations

NCT01548560 | Completed Phase 1

• 1 other identifier: FAME 02
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is a study to determine the safety of dapivirine gel and dapvirine film for healthy, HIV-uninfected women aged 18-45 years using the product for 7 daily doses.

Conditions

HIV Infections

Keywords

HIV Infections; Anti-HIV agents; HIV-1

Outcome Measures

Primary Outcomes (1)

• Number of Grade 2 or higher Adverse Events

  The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher Adverse Event as defined by the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 and the Female Genital Grading Table for Use in Microbicide Studies which is judged to be related to study product.

  5-11 weeks

Secondary Outcomes (2)

• Changes in vaginal flora and vaginal pH

  5-11 weeks

• Systemic and local absorption levels of dapivirine

  5-11 weeks

Study Arms (4)

Dapivirine Vaginal Gel

EXPERIMENTAL

Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses

Drug: Dapivirine Vaginal Film; Drug: Dapivirine Vaginal Gel

Placebo Gel

PLACEBO COMPARATOR

Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses

Drug: Dapivirine Vaginal Gel

Dapvirine Vaginal Film

EXPERIMENTAL

Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses

Drug: Dapivirine Vaginal Film; Drug: Dapivirine Vaginal Gel

Vaginal Film

PLACEBO COMPARATOR

Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses

Drug: Dapivirine Vaginal Film

Interventions

Dapivirine Vaginal Film DRUG

Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses

Dapivirine Vaginal Gel; Dapvirine Vaginal Film; Vaginal Film

Dapivirine Vaginal Gel DRUG

Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses

Dapivirine Vaginal Gel; Dapvirine Vaginal Film; Placebo Gel

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18 through 45 years (inclusive) at screening
• Able and willing to provide written informed consent to be screened for and to take part in the study.
• Able and willing to provide adequate locator information
• HIV-uninfected based on testing performed by study staff at screening (per algorithm in Appendices I)
• Per participant report, using an effective method of contraception at enrollment; hormonal method (except vaginal ring) used continuously for the past 30 days; intrauterine device (IUD inserted at least 30 days prior to enrollment); female sterilization; abstinent from sexual activity with male partner for the past 30 days; or sexual activity with vasectomized partner; and willingness to use effective method of contraception until the completion of final scheduled study visit if enrolled (approximately 35 days after enrollment)
• In general good health as determined by the site clinician
• For participants older than 21, a pap result in the 12 calendar months prior to Enrollment consistent with Grade 0 according to the Female Genital Grading Table for Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009) or satisfactory evaluation with no treatment required of non-Grade 0 Pap result per American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines or per local standard of care, in the 12 calendar months prior to the Enrollment
• Note: For participants aged 18-21, a Grade-0 or adequately evaluated abnormal Pap smear is not required as the American Society for Colposcopy and Cervical Pathology recommends initiating screening at age 21.
• Agree to be sexually abstinent from Visit 1 until the completion of Visit 3
• Agree to use study condoms between Visits 3 and 4 (if heterosexually active)
• Agree to abstain from any other intravaginal product or penetration (including sex toys, excluding tampons) until Visit 3
• Willingness to undergo all study-related assessments and follow all study-related procedures
• At screening and enrollment, agrees not to participate in other research studies involving drugs, medical devices, or vaginal products while enrolled in this trial

You may not qualify if:

• Menopause (as defined as amenorrhea for one year or more without an alternative etiology)
• Hysterectomy
• Participant report of any of the following:
• Known adverse reaction to any of the study products (ever)
• Known adverse reaction to latex (ever)
• Non- therapeutic injection drug use in the 12 months prior to Screening
• Surgical procedure involving the pelvis in the 90 days prior to enrollment (includes dilation and curettage or evacuation, and cryosurgery; does not include cervical biopsy for evaluation of an abnormal pap smear)
• Participation in a drug, spermicide and/or microbicide study in the 30 days prior to enrollment or anticipated participation in an investigational drug study in the next 8 weeks
• Pregnancy within 90 days of enrollment
• Currently lactating
• Use of a diaphragm, NuvaRing®, or spermicide for contraception
• Internal vaginal use of any device or product (except tampons) in the 7 days prior to enrollment
• Urogenital infection or suspected infection within 14 days of enrollment including: symptomatic candidiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis; or cervical infection, including N. gonorrhea, C. trachomatis, or mucopurulent cervicitis; syphilis; HSV lesions, or other sores (Note: seropositive HSV without active lesions will not be excluded); acute pelvic inflammatory disease; urinary tract infection; recent exposure to a partner with GC, CT, Trichomonas, syphilis, or NGU
• Antibiotic or antifungal therapy (vaginal or systemic) within 7 days of enrollment
• As determined by the PI, has any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease

Sponsors & Collaborators

• International Partnership for Microbicides, Inc.: lead

Study Sites (1)

Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Study Officials

• Katherine Bunge, MD MPH

  Magee Womens Hospital, UPitt

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 1, 2012
• First Posted: March 8, 2012
• Study Start: August 1, 2012
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: September 8, 2017

Record last verified: 2017-09

Locations

US (1)